Michael Stipanov, MD
Hematology & Oncology · Chattanooga, TNNPI 1255384616
Payments from drug & device makers
Across 94 payments — averaging $19.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$199
- AstraZeneca$194
- Amgen$178
- Exelixis Inc.$133
- Lilly USA, LLC$125
- E.r. Squibb & Sons, L.L.C.$118
- plus $888 from 23 others
What the payments were for
- Food & beverage$1,72994%
- Education$1066%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 18 | $199 |
| AstraZeneca | 8 | $194 |
| Amgen | 8 | $178 |
| Exelixis Inc. | 5 | $133 |
| Lilly USA, LLC | 5 | $125 |
| E.r. Squibb & Sons, L.L.C. | 6 | $118 |
| Sanofi | 3 | $110 |
| Bayer | 4 | $85 |
| Bristol Myers Squibb | 3 | $71 |
| Novartis | 4 | $68 |
| Gilead | 4 | $61 |
| Genentech USA, Inc. | 3 | $46 |
| Merck | 3 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $42 |
| Johnson & Johnson | 2 | $37 |
| Incyte Corporation | 2 | $32 |
| Tesaro, Inc. | 1 | $30 |
| Verastem, Inc. | 2 | $30 |
| Aurobindo Pharma USA, Inc. | 1 | $30 |
| Seagen Inc. | 1 | $29 |
| Jazz Pharmaceuticals Inc. | 1 | $26 |
| G1 Therapeutics, Inc. | 1 | $25 |
| ADC Therapeutics America, Inc. | 1 | $22 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| Eisai Inc. | 1 | $20 |
| Array Biopharma Inc | 1 | $16 |
| Astellas Pharma US Inc | 1 | $15 |
| AbbVie | 1 | $15 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $12 |
How this compares
$1,835 in reported general payments places this provider in the 20th percentile of 251 hematology & oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 141 | $2,342,244 |
| BrukinsaZanubrutinib | 90 | $1,212,234 |
| CalquenceAcalabrutinib Maleate | 53 | $811,670 |
| IbrancePalbociclib | 54 | $784,389 |
| VerzenioAbemaciclib | 52 | $777,859 |
| XtandiEnzalutamide | 44 | $598,857 |
| Abiraterone Acetate | 253 | $488,998 |
| JakafiRuxolitinib Phosphate | 35 | $485,844 |
| ErleadaApalutamide | 23 | $346,672 |
| PomalystPomalidomide | 15 | $312,142 |
| JaypircaPirtobrutinib | 15 | $307,227 |
| TasignaNilotinib Hcl | 12 | $230,874 |
| SprycelDasatinib | 11 | $177,508 |
| EliquisApixaban | 143 | $111,020 |
| Neulasta OnproPegfilgrastim | 13 | $66,600 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $71 | $2,342,244141 claims |
| Lilly USA, LLCVerzenio, Jaypirca | $125 | $1,085,08667 claims |
| PfizerIbrance, Eliquis | $199 | $895,409197 claims |
| AstraZenecaCalquence | $194 | $811,67053 claims |
| Astellas Pharma US IncXtandi | $15 | $598,85744 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $118 | $489,65026 claims |
| Incyte CorporationJakafi | $32 | $485,84435 claims |
| Johnson & JohnsonErleada, Xarelto | $37 | $381,60771 claims |
| NovartisTasigna | $68 | $230,87412 claims |
| AbbVieVenclexta | $15 | $65,36212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 251 hematology & oncology providers in Tennessee.
Other hematology & oncology in Chattanooga
- Bertrand AnzChattanooga$9.6M
- Edward ArrowsmithChattanooga$5.7M
- Davey DanielChattanooga$5M
- Brooke DanielChattanooga$4M
- Mark WomackChattanooga$1.9M
- Robert GrahamChattanooga$799K
- Erika HamiltonNashville$45.4M
- Ian FlinnNashville$41.2M
- Johanna BendellNashville$28.5M
- Jesus BerdejaNashville$22.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.